Антикоагулянтная терапии у пациентов, перенесших протезирование клапанов сердца механическими протезами

Приобретенные пороки сердца имеют высокую распространенность среди пациентов разных возрастных групп и являются значимой социальной проблемой. Наиболее эффективным методом лечения данной патологии является хирургическая коррекция, включающая протезирование механическими клапанами сердца с последующей постоянной антикоагулянтной терапией с применением антагонистов витамина К и постоянным контролем международного нормализованного отношения (МНО). Вопрос оптимизации подходов к терапии антикоагулянтами для указанной категории пациентов становится всё более актуальным. В настоящей работе освещены основные проблемы и возможные пути их решения для пациентов, перенесших имплантацию механического протеза и нуждающихся в постоянном приеме антагонистов витамина К.

1. Iung B., Vahanian A. Epidemiology of acquired valvular heart disease. Can. J. Cardiol. 2014;30:962-970. https://doi.org/10.1016/j.cjca.2014.03.022

2. Yesiltas M.A., Haberal І., Kuserli Y., Yildiz A., Koyuncu A.O., Ozsoy S. D. Comparison of Short and Mid-Term Mortality and Morbidity in Patients With Severe Aortic Stenosis (Intermediate/High Risk) Who Underwent Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement. Heart Surg. Forum. 2020;23(2):E212-E220. https://doi.org/10.1532/hsf.2913

3. Williams M.A., van Riet S. The On-X heart valve: mid-term results in a poorly anticoagulated population. J. Heart Valve Dis. 2006;15:80-86. https://doi.org/10.1111/j.0886-0440.2004.04084.x

4. Taniguchi S., Hashizume K., Ariyoshi T., Hisata Y., Tanigawa K., Miura T., Odate T., Matsukuma S., Nakaji S., Eishi K. Twelve years of experience with the ATS mechanical heart valve prostheses. Gen. Thorac. Cardiovasc. Surg. 2012;60(9):561-568. https://doi.org/10.1007/s11748-012-0124-1

5. Torella M., Torella D., Chiodini P., Franciulli M., Romano G., De Santo L., De Feo M., Amarelli C., Sasso F.C., Salvatore T., Ellison G.M., Indolfi C., Cotrufo M., Nappi G. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am. Heart J. 2010;160(1):171- 178. https://doi.org/10.1016/j.ahj.2010.05.005

6. Model R., Simon P., Wolner E. On-X Prosthetic Heart Valve Trial. The On-X prosthetic heart valve at five years. Ann. Thorac. Surg. 2002;74:S1312-7. https://doi.org/10.1016/S0003-4975(02)03968-1

7. Eckman M.H., Beshansky J.R., Durand-Zaleski I., Levine H.J., Pauker S.G. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? JAMA. 1990;263(11):1513- 1521. https://doi.org/10.1001/jama.1990.03440110079032

8. Salem D.N., Stein P.D., Al-Ahmad A., Bussey H.I., Horstkotte D., Miller N., Pauker S.G. Antithrombotic therapy in valvular heart disease-native and prosthetic. Chest. 2004;126(Suppl.):457S-482S. https://doi.org/10.1378/chest.126.3_suppl.457S

9. Караськов А.М., Назаров В.М., Железнев С.И. Дисфункции искусственных клапанов сердца. Новосибирск: Гео, 2008. 247 с. ISBN 978-5-9747-0125-2

10. Орловский П.И., Шевченко Ю.Л., Гриценко В.В. Искусственные клапана сердца. СПб. : ОЛМА Медиа Групп, 2007. 447 с. ISBN 978-5-373-00314-8

11. Wright I.S., Beck D.F., Marple C.D. Myocardial infarction and its treatment with anticoagulants; summary of findings in 1031 cases. Lancet. 1954;266(6802):92-95. https://doi.org/10.1016/s0140-6736(54)90838-7

12. Hirsh J., Deykin D., Poller L. "Therapeutic range" for oral anticoagulant therapy. Chest. 1986;89(2 Suppl):11S-15S. https://doi.org/10.1378/chest.89.2_supplement.11s

13. Gadboys H.L., Litwak R.S., Niemetz J., Wisch N. Role of anticoagulants in preventing embolization from prosthetic heart valves. JAMA. 1967;202:282-286. https://doi.org/10.1001/jama.1967.03130170082012

14. Friedli B., Aerichide N., Grondin P., Campeau L. Thromboembolic complications of heart valve prostheses. Am. Heart J. 1971;81:702-708. https://doi.org/10.1016/0002-8703(71)90015-9

15. Chesebro J.H., Adams P.C., Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol. 1986;8(6 Suppl B):41B-56B. https://doi.org/10.1016/s0735-1097(86)80006-7

16. Turpie A.G., Gunstensen J., Hirsh J., Nelson H., Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1(8597):1242-1245. https://doi.org/10.1016/s0140-6736(88)92070-3

17. Altman R., Rouvier J., Gurfinkel E., D'Ortencio O., Manzanel R., de La Fuente L., Favaloro R.G. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J. Thorac Cardiovasc. Surg. 1991;101(3):427-431. https://doi.org/10.1016/S0022-5223(19)36724-8

18. Stein P.D., Alpert J.S., Copeland J., Dalen J.E., Goldman S., Turpie A.G. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 1992;102(4 Suppl):445S-455S. https://doi.org/10.1378/chest.102.4_supplement.445s

19. Turpie A.G., Gent M., Laupacis A., Latour Y., Gunstensen J., Basile F., Klimek M., Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N. Engl. J. Med. 1993;329:524-529. https://doi.org/10.1056/NEJM199308193290802

20. MacIsaac S., Jaffer I.H., Belley-Cote E.P., McClure G.R., Eikelboom J.W., Whitlock R.P. How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. Circulation. 2019;140(23):1933-1942. https://doi.org/10.1161/CIRCULATIONAHA.119.041105

21. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., van der Meer F.J., Vandenbroucke J.P., Briёt E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. 1995;333(1):11-17. https://doi.org/10.1056/NEJM199507063330103

22. Acar J., Iung B., Boissel J.P., Samama M.M., Michel P.L., Teppe J.P., Pony J.C., Breton H.L., Thomas D., Isnard R., de Gevigney G., Viguier E., Sfihi A., Hanania G., Ghannem M., Mirode A., Nemoz C. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94(9):2107-2112. https://doi.org/10.1161/01.cir.94.9.2107

23. Loeliger E.A. Therapeutic target values in oral anticoagulation-justification of Dutch policy and a warning against the so-called moderate-intensity regimens Ann. Hematol. 1992;64(2):60-65. https://doi.org/10.1007/BF01715346

24. Hering D., Piper C., Bergemann R., Hillenbach C., Dahm M., Huth C., Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest. 2005;127(1):53-59. https://doi.org/10.1378/chest.127.1.53

25. Koertke H., Zittermann A., Wagner O., Secer S.; Christ of Huth, Sciangula A., Saggau W., Sack F.U., Ennker J., Cremer J., Musumeci F., Gummert J.F. Telemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants. Eur. Heart J. 2015;36(21):1297-1305. https://doi.org/10.1093/eurheartj/ehu330

26. Otto C.M., Nishimura R.A., Bonow R.O., Carabello B.A., Erwin J.P., Gentile F., Jneid H., Krieger E.V., Mack M., McLeod C., O'Gara P.T., Rigolin V.H., Sundt T.M., Thompson A., Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2021 Feb 2;143(5):e228] [published correction appears in Circulation. 2021 Mar 9;143(10):e784]. Circulation. 2021;143(5):e35-e71. https://doi.org/10.1161/CIR.0000000000000932

27. Puskas J.D., Gerdisch M., Nichols D., Fermin L., Rhenman B., Kapoor D., Copeland J., Quinn R., Hughes G.C., Azar H., McGrath M., Wait M., Kong B., Martin T., Douville E.C., Meyer S., Ye J., Jamieson W.R.E., Landvater L., Hagberg R., Trotter T., Armitage J., Askew J., Accola K., Levy P., Duncan D., Yanagawa B., Ely J., Graeve A. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J. Am. Coll. Cardiol. 2018;71(24):2717-2726. https://doi.org/10.1016/j.jacc.2018.03.535.

28. Gupta S., Belley-Cote E.P., Sarkaria A., Pandey A., Spence J., McClure G., Panchal P., Jaffer I.H., An K., Eikelboom J., Whitlock R.P. International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. Thromb Haemost. 2018;118(5):906-913. https://doi.org/10.1055/s-0038-1637755

29. Brenner B. Haemostatic changes in pregnancy. Thromb. Res. 2004;114(5- 6):409-414. https://doi.org/10.1016/j.thromres.2004.08.004.

30. Burke N., Flood K., Murray A., Cotter B., Dempsey M., Fay L., Dicker P., Geary M.P., Kenny D., Malone F.D. Platelet reactivity changes significantly throughout all trimesters of pregnancy compared with the nonpregnant state: a prospective study. BJOG. 2013;120:1599-1604. https://doi.org/10.1111/1471-0528.12394

31. Holmes V.A., Wallace J.M. Haemostasis in normal pregnancy: a balancing act? Biochem. Soc. Trans. 2005;33:428-432. https://doi.org/10.1042/BST0330428

32. Ansari J., Carvalho B., Shafer S.L., Flood P. Pharmacokinetics and pharmacodynamics of drugs commonly used in pregnancy and parturition. Anesth. Analg. 2016;122:786-804. https://doi.org/10.1097/01.aoa.0000504701.05570.8d

33. Krauer B., Krauer F. Drug kinetics in pregnancy. Clin. Pharmacokinet. 1977;2:167-181. https://doi.org/10.2165/00003088-197702030-00002

34. Toyoda K. Antithrombotic therapy for pregnant women. Neurol. Med. Chir (Tokyo). 2013;53(8):526-530. https://doi.org/10.2176/nmc.53.526

35. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., O'Gara P.T., Ruiz C.E., Skubas N.J., Sorajja P., Sundt T.M., Thomas J.D. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014 Jun 10;129(23):e650]. Circulation. 2014;129(23):2440-2492. https://doi.org/10.1161/CIR.0000000000000029

36. Goland S., Elkayam U. Anticoagulation in pregnancy. Cardiol. Clin. 2012;30(3):395-405. https://doi.org/10.1016/j.ccl.2012.05.003

37. McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thromb. Res. 2011;127 Suppl 3:S56-S60. https://doi.org/10.1016/S0049-3848(11)70016-0

38. Cannegieter S.C., Rosendaal F.R., Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635-641. https://doi.org/10.1161/01.CIR.89.2.635

39. Makhija N., Tayade S., Tilva H., Chadha A., Thatere U. Pregnancy After Cardiac Surgery. Cureus. 2022;14(11):e31133. https://doi.org/10.7759/cureus.31133

40. Nadeem S., Khilji S.A., Ali F., Jalal A. Continued use of Warfarin in lower dose has safe maternal and neonatal outcomes in pregnant women with Prosthetic Heart Valves. Pak. J. Med. Sci. 2021;37(4):933-938. https://doi.org/10.12669/pjms.37.4.3924

41. Xu Z., Fan J., Luo X., Zhang W.B., Ma J., Lin Y.B., Ma S.H., Chen X., Wang Z.P., Ou J.S., Zhang X. Anticoagulation Regimens During Pregnancy in Patients With Mechanical Heart Valves: A Systematic Review and Meta-analysis. Can. J. Cardiol. 2016;32(10):1248.e1-1248. e9. https://doi.org/10.1016/j.cjca.2015.11.005

42. van Driel D., Wesseling J., Sauer P.J., Touwen B.C., van der Veer E., Heymans H.S. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66(3):127-140. https://doi.org/10.1002/tera.10054

43. Chan W.S., Anand S., Ginsberg J.S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch. Intern. Med. 2000;160(2):191-196. https://doi.org/10.1001/archinte.160.2.191

44. Wang J., Li K., Li H., Zhu W., Sun H., Lu C. Comparison of anticoagulation regimens for pregnant women with prosthetic heart valves: A meta-analysis of prospective studies. Cardiovasc. Ther. 2017;35(6):10.1111/1755-5922.12292. https://doi.org/10.1111/1755-5922.12292

45. Ayad S.W., Hassanein M.M., Mohamed E.A., Gohar A.M. Maternal and Fetal Outcomes in Pregnant Women with a Prosthetic Mechanical Heart Valve. Clin. Med. Insights. Cardiol. 2016;10:11-17. https://doi.org/10.4137/CMC.S36740

46. Leonardi F., Maria N., Villa E. Anticoagulation in cirrhosis: a new paradigm?. Clin. Mol. Hepatol. 2017;23(1):13-21. https://doi.org/10.3350/cmh.2016.0110

47. Self T.H., Owens R.E., Sakaan S.A., Wallace J.L., Sands C.W., Howard-Thompson A. Effect of diseases on response to vitamin K antagonists. Curr. Med. Res. Opin. 2016;32(4):613-620. https://doi.org/10.1185/03007995.2015.1134464

48. Leonardi F., Maria N., Villa E. Anticoagulation in cirrhosis: a new paradigm?. Clin. Mol. Hepatol. 2017;23(1):13-21. https://doi.org/10.3350/cmh.2016.0110

49. McMurry H.S., Jou J., Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur. J. Haematol. 2021;107(4):383-392. https://doi.org/10.1111/ejh.13688

50. Rijken D.C., Kock E.L., Guimaraes A.H., Talens S., Darwish Murad S., Janssen H.L., Leebeek F.W. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J. Thromb. Haemost. 2012;10(10):1538-7836. https://doi.org/10.1111/j.1538-7836.2012.04901.x

51. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N. Engl. J. Med. 2011;365:147-156. https://doi.org/10.1056/NEJMra1011170

52. McMurry H.S., Jou J., Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur. J. Haematol. 2021;107(4):383-392. . https://doi.org/10.1111/ejh.13688

53. Brigden M.L., Kay C., Le A., Graydon C., McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an outpatient population. Am. J. Hematol. 1998;59:22-27. https://doi.org/10.1002/(SICI)1096-8652(199809)59:1<22::AID-AJH5>3.0.CO;2-1

54. Gallus A.S., Lucas C.R., Hirsh J. Coagulation studies in patients with acute infectious hepatitis. Br. J. Haematol. 1972;22(6):761-771. https://doi.org/10.1111/j.1365-2141.1972.tb05720.x

55. Lisman T., Kamphuisen P.W., Northup P.G., Porte R.J. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J. Hepatol. 2013;59(2):358-366. https://doi.org/10.1016/j.jhep.2013.03.027

56. Hoffman M., Monroe D.M. Coagulation 2006: a modern view of hemostasis. Hematol. Oncol. Clin. North. Am. 2007;21(1):1-11. https://doi.org/10.1016/j.hoc.2006.11.004

57. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878-885. https://doi.org/10.1182/blood-2010-02-261891

58. Steuber T.D., Howard M.L., Nisly S.A. Direct Oral Anticoagulants in Chronic Liver Disease. Annals of Pharmacotherapy. 2019;53(10):1042- 1049. https://doi.org/10.1177/1060028019841582

59. Gallagher J., Biesboer A.N., Killian A.J. Pharmacologic Issues in Liver Disease. Crit. Care Clin. 2016;32(3):397-410. https://doi.org/10.1016/j.ccc.2016.02.003

60. Kumar S., Lim E., Covic A., Verhamme P., Gale C.P., Camm A.J., Goldsmith D.Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2019;74(17):2204-2215. https://doi.org/10.1016/j.jacc.2019.08.1031

61. Potpara T.S., Ferro C.J., Lip G.Y.H. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat. Rev. Nephrol. 2018;14(5):337-351. https://doi.org/10.1038/nrneph.2018.19

62. Lau Y.C., Proietti M., Guiducci E., Blann A.D., Lip G.Y.H. Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease [published correction appears in J Am Coll Cardiol. 2016 Dec 27;68(25):2921]. J. Am. Coll. Cardiol. 2016;68(13):1452-1464. https://doi.org/10.1016/j.jacc.2016.06.057

63. Aursulesei V., Costache I.I. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin. Cardiol. 2019;42(8):774-782. https://doi.org/10.1002/clc.23196

64. Limdi N.A., Nolin T.D., Booth S.L., Centi A., Marques M.B., Crowley M.R., Allon M., Beasley T.M. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am. J. Kidney Dis. 2015;65(5):701-709. https://doi.org/10.1053/j.ajkd.2014.11.004

65. Sakaan S.A., Hudson J.Q., Oliphant C.S., Tolley E.A., Cummings C., Alabdan N.A., Self T.H. Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease. Pharmacotherapy. 2014;34(7):695-702. https://doi.org/10.1002/phar.1445

66. Limdi N.A., Beasley T.M., Baird M.F., Goldstein J.A., McGwin G., Arnett D.K., Acton R.T., Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 2009;20(4):912-921. https://doi.org/10.1681/asn.2008070802